The efficacy of modified hemostasis forceps for gastric ESD

The efficacy of modified hemostasis forceps for gastric ESD - The efficacy of modified hemostasis forceps

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011458

Enrollment

Registered

2013-08-25

Start date

2013-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

early gastric cancer

Interventions

standard hemostasis forceps modified hemostasis forceps

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. early gastric cancer that meet the criteria for ESD proposed by Japanese Gastric Cancer Society(those with a preoperative diagnosis of differentiated type intramucosal cancer without ulcer findings; differentiated type intramucosal cancer that was no longer than 3cm in diameter with ulcer findings; differentiated-type minute invasive submucosal cancer (invasion less than 0.5mm below the muscularis mucosa) that was no longer than 3cm in diameter; and undifferentiated-type intramucosal cancer that was no longer than 2 cm in diameter without ulcer finding.) 2. tumor size less than 60mm in diameter

Exclusion criteria

Exclusion criteria: 1. leison including ulcer 2. patient recieving antithrombotic medication 3. patients with severe liver cirrhosis 4. dialysis patient 5. patient with compromized blood clotting

Design outcomes

Primary

Measure	Time frame
hemostatic time for initial bleeding	—

Secondary

Measure	Time frame
hemostatic time for all bleeding procedure time complication	—

Countries

Japan

Contacts

Public ContactShinwa Tanaka

Kobe University Hospital Endoscopy

tanakas@med.kobe-u.ac.jp078-382-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026